Jeffrey Wolf, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jeffrey Wolf, MD

Clinical Professor, Department of Medicine, UCSF; and Director, Myeloma Program, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 353-2421 (appts)
Box 0324, UCSF, San Francisco, CA 94143-0324

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Hematopoietic Malignancies

Education

Washington University; St. Louis, Missouri, A.B., 1968, Chemistry
University of Illinois Medical Center, Chicago, IL, M.D., 1972
University of California, San Diego, Intern, 1972-1973, Internal Medicine
University of California, San Diego, Residency, 1973-1974, Internal Medicine
University of California, San Diego, Residency, 1975-1976, Internal Medicine
Fred Hutchinson Cancer Research Center, Seattle, Washington, Fellowship, January-February, 1977, Bone Marrow Transplantation
University of California San Francisco, San Francisco, Fellowship, 1976-1979, Hematology/Oncology


Professional Experience

  • 1979-1982
    Staff Physician, City of Hope National Medical Center, Duarte, California, Hematology and Bone Marrow Transplantation
  • 1982-2007
    Director of Stem Cell Transplantation Program, Practice of Hematology and Oncology, Alta Bates Summit Medical Center, Berkeley, California
  • 2007-present
    Clinical Professor of Medicine, Division of Hematology/Oncology, University of California, San Francisco, California
  • 2007-2010
    Director, Clinical Research, Division of Hematology/Oncology, University of California, San Francisco, California
  • 2007-present
    Director, Myeloma Program, Division of Hematology/Oncology, University of California, San Francisco, California

Honors & Awards

  • 1968-1972
    Bamberger Scholarship, University of Illinois, School of Medicine

Selected Publications

  1. A phase I study of targeted, dose-escalated intravenous busulfan in combination with Etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83.
    View on PubMed
  2. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91.
    View on PubMed
  3. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
    View on PubMed
  4. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Sep; 53(9):1820-3.
    View on PubMed
  5. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol. 2010 Aug; 150(4):428-37.
    View on PubMed
  6. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010 Jul; 24(7):1350-6.
    View on PubMed
  7. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol. 2010; 3:9.
    View on PubMed
  8. Myeloma-associated polyneuropathy responding to lenalidomide. Neurology. 2009 Sep 8; 73(10):812-3.
    View on PubMed
  9. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol. 2009 Sep; 146(6):619-26.
    View on PubMed
  10. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005 Jun; 129(6):776-83.
    View on PubMed
  11. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant. 2002 Feb; 29(4):297-301.
    View on PubMed
  12. Trisomy 4 and double minutes in acute myeloid leukemia: further evidence that double minutes can occur as the primary cytogenetic abnormality. Cancer Genet Cytogenet. 2000 Sep; 121(2):212-5.
    View on PubMed
  13. High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant. 2000 Aug; 26(3):257-68.
    View on PubMed
  14. Monosomy 16 as the sole abnormality in myeloid malignancies. Cancer Genet Cytogenet. 2000 Apr 15; 118(2):163-6.
    View on PubMed
  15. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. Biol Blood Marrow Transplant. 2000; 6(5):496-505.
    View on PubMed
  16. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant. 1998 Nov; 22(9):865-72.
    View on PubMed
  17. Mismatches for two major and one minor histocompatibility antigen correlate with a patient's rejection of a bone marrow graft from a serologically HLA-identical sibling. Biol Blood Marrow Transplant. 1997 Nov; 3(5):255-60.
    View on PubMed
  18. High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma. Prog Clin Biol Res. 1994; 389:505-11.
    View on PubMed
  19. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. Semin Oncol. 1993 Aug; 20(4 Suppl 4):40-8; quiz 49.
    View on PubMed
  20. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 1993 Jan 15; 81(2):311-8.
    View on PubMed

Go to UCSF Profiles, powered by CTSI